What is Wixela Inhub?
Wixela Inhub is a prescription inhaled medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema [1]. It is a combination product containing fluticasone propionate and salmeterol [1]. Fluticasone propionate is an inhaled corticosteroid that reduces inflammation in the airways, and salmeterol is a long-acting beta2-adrenergic agonist (LABA) that helps keep the airways open [1].
What medications are similar to Wixela Inhub?
Several inhaled medications are available that contain a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) for COPD management, similar to Wixela Inhub. These include:
* Budesonide and formoterol fumarate dihydrate (Symbicort): This combination also uses an ICS and a LABA for COPD maintenance [2].
* Fluticasone furoate and vilanterol (Breo Ellipta): This medication also combines an ICS and a LABA [3].
* Momalonesone furoate and formoterol fumarate dihydrate (Dulera): This is another ICS/LABA combination therapy [4].
* Inhaled corticosteroid monotherapy: While not a direct alternative to the combination therapy of Wixela, inhaled corticosteroids alone, such as fluticasone propionate (Flovent) or budesonide (Pulmicort), are used for COPD treatment, particularly when inflammation is a significant component [5].
* Long-acting beta2-adrenergic agonist monotherapy: LABAs alone, such as salmeterol (Serevent) or formoterol (Foradil), are also used for COPD maintenance but are generally recommended to be used in conjunction with an ICS in patients with a history of exacerbations [6].
The choice of alternative medication depends on individual patient needs, response to treatment, and physician recommendations.
How do these alternatives compare to Wixela Inhub?
The primary difference between Wixela Inhub and its alternatives lies in the specific active ingredients and their delivery devices. Wixela Inhub contains fluticasone propionate and salmeterol [1]. Other ICS/LABA combinations utilize different corticosteroids or LABAs, or both. For example, Symbicort uses budesonide and formoterol [2], Breo Ellipta uses fluticasone furoate and vilanterol [3], and Dulera uses mometasone furoate and formoterol [4].
The efficacy and safety profiles of these combination therapies are generally similar for their approved indications. However, individual patient responses can vary, and a physician may choose one combination over another based on factors such as the patient's specific symptoms, exacerbation history, and tolerability of the medication and its delivery device [7]. The inhaler device itself can also be a distinguishing factor, with different devices having unique mechanisms of action for delivering the medication to the lungs [8].
When does the patent for Wixela Inhub expire?
Drug patent information, including expiration dates, can be complex and subject to change due to various legal and regulatory factors. For precise and up-to-date information on Wixela Inhub's patent status and expiration, consulting specialized resources is recommended. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and can provide detailed information on patent expiry dates, as well as information on generic and biosimilar competition [9].
Can generic versions of Wixela Inhub be made?
The development and availability of generic versions of a medication are contingent upon patent expiry and regulatory approval. Once patents protecting Wixela Inhub expire and regulatory bodies approve a generic equivalent, it can be manufactured and marketed. The generic version would need to demonstrate bioequivalence to the brand-name drug [10].
What are the side effects of Wixela Inhub?
Common side effects associated with Wixela Inhub include upper respiratory tract infection, pneumonia, headache, hoarseness, and oral candidiasis (thrush) [1]. Patients are advised to rinse their mouths with water after each use to help prevent thrush [1]. More serious side effects can occur, and patients should consult their healthcare provider if they experience any concerning symptoms [1].
What are the risks of using ICS/LABA medications?
Inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) medications, including Wixela Inhub, carry potential risks. These include an increased risk of pneumonia in patients with COPD [1]. Other potential risks associated with ICS/LABA use can include oral candidiasis, increased blood pressure, fast or irregular heartbeats, tremors, and nervous system effects [1]. Long-term use of ICS may also be associated with a decrease in bone mineral density and eye changes, such as glaucoma and cataracts [1].
Sources
1. https://www.drugpatentwatch.com/drugs/wixela-inhub
2. https://www.drugpatentwatch.com/drugs/symbicort
3. https://www.drugpatentwatch.com/drugs/breo-ellipta
4. https://www.drugpatentwatch.com/drugs/dulera
5. https://www.drugpatentwatch.com/drugs/flovent-hfa
6. https://www.drugpatentwatch.com/drugs/serevent-diskus
7. https://www.uptodate.com/contents/initial-treatment-of-moderate-and-severe-copd-using-bronchodilators-and-inhaled-corticosteroids
8. https://www. Lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment/medications
9. https://www.drugpatentwatch.com/
10. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/drug-pyridazinone-and-related-generic-drugs